BioPharma DiveOriginal article
Biogen-backed Estuary nabs $93M for liver disease gene therapy
Positive
AI Analysis
Summary
Biogen-backed Estuary raised a $93M Series A round led by RA Capital. The funds will support development of two genetic medicines for autosomal dominant polycystic kidney disease (ADPKD).
Outcome Details
$93M Series A round led by RA Capital to fund development of two genetic medicines for ADPKD
Importance:5/10
Sentiment:
0.50
Series Agene therapygenetic medicineADPKDventure financingkidney disease
Related Companies
Read the original article
Published by BioPharma Dive on October 16, 2026 10:30 AM